Moderna Inc
Change company Symbol lookup
Select an option...
MRNA Moderna Inc
XOM Exxon Mobil Corp
EPD Enterprise Products Partners LP
STLB Sterling Business Solutions Inc
CITY Avalon Correctional Services Inc
TEVJF Teva Pharmaceutical Industries Ltd
UMBF UMB Financial Corp
OXM Oxford Industries Inc
ICON Iconix Brand Group Inc
BAC Bank of America Corp
Go

Health Care : Biotechnology | Mid Cap Blend
Company profile

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Price
Delayed
$65.15
Day's Change
-3.85 (-5.58%)
Bid
--
Ask
--
B/A Size
--
Day's High
66.59
Day's Low
63.00
Volume
(Heavy Day)

Today's volume of 3,929,252 shares is on pace to be much greater than MRNA's 10-day average volume of 37,548,014 shares.

3,929,252

Company Profile

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
508.84x
Price/Book (MRQ)
15.56x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

April 2020
Current Month
22.2M
Previous Month
23.9M
Percent of Float
7.59%
Days to Cover
1.2002 Days

Share Information

MRNA is in a share class of common stock
Float
292.4M
Shares Outstanding
387.7M
Institutions Holding Shares
359
49.64%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Noubar B. Afeyan
  • Stephen HogePres.
  • Stephane BancelCEO
  • Lorence KimCFO
  • Tracey Franklin

Address

Insider Trading

During the most recent quarter, 53K shares were bought, and 3M shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.